Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

May 14, 2024 07:35 ET
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the...
May 14, 2024 07:30 ET
2024 Rabbet Report: Risk Management and Automation Emerge as Top Priorities in Construction Finance
Rabbet, the leading provider of construction finance software, today released its highly anticipated 2024 State of Construction Finance Report. The annual report provides critical insights into the evolving dynamics of construction finance, this...
May 14, 2024 07:30 ET
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024. "During the first quarter, we made significant strides in advancing both our...
May 14, 2024 07:30 ET
Alimera Sciences Reports First Quarter 2024 Results
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial...
May 14, 2024 07:30 ET
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders...
May 14, 2024 07:30 ET
Batteh Named Saia’s Chief Financial Officer
Saia, Inc. (Nasdaq: SAIA), a leading transportation provider offering national less-than-truckload (LTL), non-asset truckload, expedited and logistics services, today announced that Matthew Batteh has been promoted to Executive Vice President and...
May 14, 2024 07:30 ET
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America...
May 14, 2024 07:30 ET
Entourage Health to Hold First Quarter 2024 Financial Results Call on May 28
Entourage Health Corp. (TSX-V:ENTG) (OTCQX: ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products announced today it will file its first quarter 2024 financial statements and...
May 14, 2024 07:30 ET
ETFS Capital Calls on WisdomTree to Stop Fighting Stockholders and Run a Strategic Process
ETFS Capital Limited (“ETFS Capital”), the largest combined owner of common stock, $0.01 par value (the “Common Stock”), and Series A Non-Voting Convertible Preferred Stock (the “Series A Preferred Stock”) of WisdomTree, Inc. (“WisdomTree” or the...
May 14, 2024 07:30 ET
FitLife Brands Announces First Quarter 2024 Results
FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the first quarter ended March 31, 2024. Highlights...
May 14, 2024 07:30 ET
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the...
May 14, 2024 07:30 ET
HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio
HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity"), the leader in Health Savings Account (HSA) and consumer-directed benefits administration, is pleased to announce the completed transfer of Conduent’s (Nasdaq: CNDT) BenefitWallet HSA portfolio....
May 14, 2024 07:30 ET
Kroma Announces Spectrum’s Launch Alongside Expansion Plans
Kroma has unveiled the highly anticipated launch of Spectrum, an advanced, native, staking service that aims to revolutionize the Ethereum Layer-2 landscape. Spectrum will commence operations on the 14th of May, 2024, and is designed to provide...
May 14, 2024 07:30 ET
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has completed enrollment of 85 patients in the Phase 2...
May 14, 2024 07:30 ET
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q 2024Use of proceeds from recent capital raise...
May 14, 2024 07:30 ET
MiNK Reports First Quarter 2024 Results
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other...
May 14, 2024 07:30 ET
nCino Announces Timing of its First Quarter Fiscal Year 2025 Financial Results Conference Call
nCino, Inc. (NASDAQ: NCNO),  a pioneer in cloud banking for the global financial services industry, will report financial results for its first quarter ended April 30, 2024, after the market close on Wednesday, May 29, 2024. nCino will host a...
May 14, 2024 07:30 ET
NowVertical Welcomes David Doritty as Independent Director
NowVertical Group Inc. (“NowVertical” or the “Company”) (TSX-V: NOW) (OTCQB: NOWVF), is pleased to announce the appointment of David Doritty, who currently serves as the Vice-Chair at Echelon Wealth Partners, as an independent director on...
May 14, 2024 07:30 ET
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced topline data from a 12-week, randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) conducted at Massachusetts General Hospital evaluating change in total collagen...
May 14, 2024 07:30 ET
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has...